Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer

Xiuwen Guan; Fei Ma; Binghe Xu

doi:10.1002/cai2.21

Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer

Xiuwen Guan
, Fei Ma
, Binghe Xu

医学部

Chinese Academy of Medical Sciences

科研成果: 期刊稿件 › 评论/辩论

7 引用（Scopus）

源语言	英语
页（从-至）	119-123
页数	5
期刊	Cancer Innovation
卷	1
期	2
DOI	https://doi.org/10.1002/cai2.21
出版状态	已出版 - 8月 2022

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

可持续发展目标 3 良好健康与福祉

访问文件

10.1002/cai2.21

其它文件与链接

链接到 Scopus 的出版物

引用此

@article{79d35a5bd383434a8a44ab63498a6761,

title = "Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer",

keywords = "breast cancer, HER2-targeted therapy, tyrosine kinase inhibitor",

author = "Xiuwen Guan and Fei Ma and Binghe Xu",

year = "2022",

month = aug,

doi = "10.1002/cai2.21",

language = "英语",

volume = "1",

pages = "119--123",

journal = "Cancer Innovation",

issn = "2770-9191",

publisher = "John Wiley and Sons Inc",

number = "2",

}

TY - JOUR

T1 - Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer

AU - Guan, Xiuwen

AU - Ma, Fei

AU - Xu, Binghe

PY - 2022/8

Y1 - 2022/8

KW - breast cancer

KW - HER2-targeted therapy

KW - tyrosine kinase inhibitor

UR - https://www.scopus.com/pages/publications/85162279824

U2 - 10.1002/cai2.21

DO - 10.1002/cai2.21

M3 - 评论/辩论

AN - SCOPUS:85162279824

SN - 2770-9191

VL - 1

SP - 119

EP - 123

JO - Cancer Innovation

JF - Cancer Innovation

IS - 2

ER -